- Home
- NATR vs CLLS Comparison
NATR vs CLLS Comparison
Compare NATR & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NATR | CLLS |
|---|---|---|
| Founded | 1972 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.4M | 299.0M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | NATR | CLLS |
|---|---|---|
| Price | $21.90 | $4.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $21.33 | $8.00 |
| AVG Volume (30 Days) | 114.5K | ★ 133.9K |
| Earning Date | 11-06-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $474,542,000.00 | $82,551,000.00 |
| Revenue This Year | $7.30 | $32.58 |
| Revenue Next Year | $3.44 | N/A |
| P/E Ratio | $27.66 | ★ N/A |
| Revenue Growth | 6.62 | ★ 129.04 |
| 52 Week Low | $11.01 | $1.10 |
| 52 Week High | $24.12 | $5.48 |
Technical Indicators
Market Signals| Indicator | NATR | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 60.54 | 49.34 |
| Support Level | $21.63 | $4.47 |
| Resistance Level | $23.03 | $5.45 |
| Average True Range (ATR) | 0.94 | 0.30 |
| MACD | -0.12 | -0.12 |
| Stochastic Oscillator | 46.83 | 31.17 |
Price Performance
Historical ComparisonAbout NATR Nature's Sunshine Products Inc.
Natures Sunshine Products Inc is a natural health and wellness company, predominantly engaged in the manufacturing and selling of nutritional and personal care products. It offers products related to Weight management, General health, Cardiovascular, Digestive, Immune, and Personal care. The company operates in four segments namely, Asia which is also its key revenue generating market, Europe, North America, Latin America, and Other.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.